Product image 1

Strong TYMS staining of a large fraction of thymic lymphocytes.

Staining Pattern in Normal Tissues

Manual protocol

Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target Retrieval Solution buffer. Apply HMV305 at a dilution of 1:150 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.

Brain
CerebrumNegative
CerebellumNegative
Endocrine tissues
ThyroidNegative
ParathyroidNegative
Adrenal glandNegative
Pituitary glandNegative
Respiratory system
Respiratory epitheliumNegative
LungNegative
Gastrointestinal tract
Salivary glandsNegative
EsophagusNegative
StomachNegative
DuodenumNegative
Small intestineNegative
AppendixWeak to moderate, nuclear and cytoplasmic TYMS staining of a fraction of crypt epithelial cells while staining is strong in many lymphocytic cells
ColonNegative
RectumWeak to moderate, nuclear and cytoplasmic TYMS staining of a large subset of crypt epithelial cells.
Liver, Gallbladder, Pancreas
LiverNegative
GallbladderWeak to moderate, nuclear and cytoplasmic TYMS staining of a subset of epithelial cells.
PancreasWeak to moderate, nuclear and cytoplasmic TYMS staining of very few epithelial cells.
Genitourinary
KidneyNegative
UrotheliumNegative
Male tissues
ProstateNegative
Seminal VesiclesNegative
TestisWeak to moderate, nuclear and cytoplasmic TYMS staining of spermatocytes.
EpididymisNegative
Female tissues
BreastNegative
Uterus, myometriumNegative
Uterus, ectocervixNegative
Uterus, endocervixNegative
Uterus, endometriumNegative
Fallopian tubeNegative
OvaryNegative
Placenta earlyNegative
Placenta matureVariable, weak to strong, nuclear and cytoplasmic TYMS staining of few cells (trophoblast, endothelial)
AmnionNegative
ChorionNegative
Skin
EpidermisNegative
Sebaceous glandsNegative
Muscle, connective & soft tissues
Heart muscleNegative
Skeletal muscleNegative
Smooth muscleNegative
Vessel wallsNegative
FatNegative
StromaNegative
EndotheliumNegative
Bone marrow & lymphoid tissues
Bone marrowModerate to strong, nuclear and cytoplasmic TYMS staining of a large subset of hematopoetic cells.
Lymph nodeStrong TYMS staining of a fraction of lymphocytic cells.
SpleenModerate to strong TYMS staining of a fraction of lymphocytic cells.
ThymusStrong TYMS staining of a large fraction of lymphocytes.
TonsilNegative

TYMS

(HMV305)

TYMS is a critical enzyme for thymidine synthesis and folate metabolism.

Select Format
Select Volume
From €295.00
excl. shipping costs and taxes
TYMS (HMV305)
€295.00

Details

Type
Recombinant Rabbit monoclonal / IgG
Clone
HMV305
Reactivity
Human

More product details

Biology behind

Thymidylate synthase (TS, TYMS) is a 32-35kD enzyme which is coded by the TYMS gene at 18p11.32. TYMS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) which is one of the nucleotides forming the DNA. TYMS is essential for DNA synthesis because it represents the only de novo pathway for production of thymidine and it also is the only enzyme in folate metabolism that can oxidize the 5,10-methylenetetrahydrofolate during one-carbon transfer. Therefore, TYMS is critical for regulating the supply of all 4 DNA precursors for DNA replication. In-vitro studies have shown that upregulation of TYMS is sufficient to transform immortalized mammalian cells to a malignant phenotype. TYMS is an important target for several chemotherapeutic drugs including 5-fluorouracil (5-FU). It has been suggested that tumors with low-levels of TYMS may show to a better response to 5-FU than those with high-level expression. In normal tissues, TYMS expression is ubiquitous but too low for detection by immunohistochemistry in most tissues. TYMS expression is highest in thymus, bone marrow, tonsil, lymph nodes and the testis. Among cancers, TYMS expression is highly variable between individual tumors. At least in a fraction of tumors, high TYMS expression occurs in a broad range of different tumor entities.

Protocol Recommendations

Potential Research Applications

Evidence For Specificity In I H C